Healthcare teamwork placeholder

Our Governance

Governance as the strong foundation of SANBS’ business

Healthcare teamwork placeholder

Our Governance

Reporting frameworks, process and combined assurance

Clinical Governance Committee

SANBS Purpose Icon
Committee member

Committee purpose and how it contributes to value creation

The overarching role of the committee is to:

  • Assist the Board to oversee the quality, safety and sufficiency of blood products and related services as well as the safety of donors, recipients of transfused blood products and employees
  • Guide the Executive management team in the development and achievement of business practices and processes to ensure the above oversight goals

Specifically excluded from the role of the committee is the occupational health and safety of employees. Health matters are included in the role of the HR & REMCO. In addition, GSEC receives a report on the safety aspects.

Members of the committee during the period 1 April 2024 to 31 March 2025

  • Dr Manickavallie Vaithilingum (Chairperson)
  • Ms Faith Burn
  • Dr Nomusa Mashigo*
  • Mr Thabo Mokgathla
  • Dr Mada Ferreira*
  • Dr Gunvant Goolab**
  • Dr Sipho Kabane**
  • Ms Lerato Molefe**
  • Dr Karin van den Berg (Executive)

* Co-opted members of the committee
** from 27 November 2024

Declaration

  • The committee has executed its responsibilities in accordance with its Board approved mandate
Attendance

  • 100%

Key focus areas and value creating activities for the period under review

The committee's primary focus remained to ensure the safety of donors, recipients and employees while SANBS implemented the final year of the iHEALTh strategy and reinforced its role as a fundamental part of the healthcare ecosystem. Key issues addressed include:

Human centred donor care

  • Oversight of the execution of the Donor Iron Strategy which places emphasis on providing donors with more tolerable iron tablets, improved communication with donors and employees, education on the importance of iron testing and supplementation, and further research into factors associated with and the outcomes of iron deficiency among blood donors, especially young female donors
    • Cheliron Forte was recommended in FY24 as the appropriate iron replacement tablet
    • The introduction of Cheliron Forte has increased iron tablet uptake among donors, likely due to its low reported side effects and extensive donor education on SANBS social media platforms prior to its launch
    • Considered the results of a survey on donor uptake, tolerability, and impact on iron status
Blood collections

  • The committee noted FY25’s significant success for the Whole Blood Group O Programme, achieving the highest number of Group O units collected in five years and maintaining an average national days cover of seven days. This stability allowed SANBS to avoid cutbacks and reduce weekend and overtime work without compromising supply
  • Strides were made in expanding and diversifying the donor panel through new blood drives and targeted promotions, which was crucial for building resilience in the blood supply chain
  • Noted the increase in whole blood collections from Black donors, who now make up 54% of the donor panel and are a testament to the success of our transformation journey
  • Noted ongoing effective stakeholder engagement:
    • Prescriber engagement: Ongoing training on the appropriate use of group O red cell products and patient blood management has raised awareness among medical professionals
    • Donor engagement: Campaigns focused on encouraging youth aged 16 to 24 to donate blood and emphasising the importance of giving the gift of life. These include outreach in schools and universities and featured social media promotions, campaign videos, and special events. See details on the increase in first time donors
Blood issuing

  • Noted the arrival of a new 20-unit haemobank SMART fridge in the country that will be used for testing the stability of 3G/4G connectivity
  • Monitored causes of process gaps and staff errors: Incidents of administrative errors were found to be primarily related to the manual transcribing of information into digital systems, insufficient or inadequate equipment and staff training needs. A major intervention to address these gaps and challenges -was implemented, leading to a decline in such errors
Platelet Strategy

The Platelet Strategy aims to ensure a sufficient platelet supply through increased donor recruitment, optimised collections, and clinician education on this scarce resource. Q4 saw the highest apheresis platelet collections in over five years, enabling the team to meet the demand during a particularly challenging quarter. Ongoing refinement of the Platelet Strategy 3.0 will be integrated into routine operations, with careful monitoring of product availability and expirations.

Patient Blood Management (PBM)

Noted that SANBS continues to be actively involved in and leads PBM initiatives to enhance the appropriate use of blood and blood products, thus optimising patient outcomes.

Blood Establishment Computer System (BECS)

Noted that the project has transitioned to full maintenance mode, following resolution of previously outstanding critical tickets. The remaining issues are managed as new requests.

Quality

All SANBS collection sites and core laboratories hold ISO 15189 accreditation. Compromised safety and quality of blood products risks remains well managed, backed by:

  • Ongoing accreditation of SANBS sites to relevant national and international standards by independent bodies
  • Continuous monitoring of the safety and quality of our blood products through medico-legal reports, the National Haemovigilance Committee (NHVC) reports, and Quality and IPC reports

Harmonisation of standards: The overall quality management system at SANBS is robust and effectively managed, reflecting management's commitment to quality and continuous improvement. SANBS received ISO 9001 accreditation and has successfully maintained its ISO 20387 accreditation and has achieved positive outcomes for ISO 17043 and ISO 13485, confirming its dedication to high standards in quality management.

Product Compliance: Monitoring and reporting product compliance to standards has been challenging since the eProgesa launch. A cross-functional team from ICT Business Applications and Business Intelligence is working to address these issues and identify solutions, with corrections set to be implemented at the start of FY26. Overall product compliance was maintained despite these challenges

Maintained the Joint Accreditation Committee ISCT-EBMT (JACIE) (cellular therapies) and the European Federation for Immunogenetics (EFI) (tissue immunology). With these achievements, SANBS realised the goal of having all areas of the business independently accredited to the relevant international standards

Medico-legal

Reviewed and approved SANBS’ medical malpractice insurance

Closely monitored potential medico-legal cases.

It takes more than one heart to save a life. At SANBS, we serve with heart, together with every donor, every colleague, and every life touched by our mission.